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CRISPR/Cas9 technology offers novel approaches for the development of new therapies for
many unmet clinical needs, including a signiﬁcant number of inherited monogenic diseases.
However, in vivo correction of disease-causing genes is still inefﬁcient, especially for those
diseases without selective advantage for corrected cells. We reasoned that substrate
reduction therapies (SRT) targeting non-essential enzymes could provide an attractive
alternative. Here we evaluate the therapeutic efﬁcacy of an in vivo CRISPR/Cas9-mediated
SRT to treat primary hyperoxaluria type I (PH1), a rare inborn dysfunction in glyoxylate
metabolism that results in excessive hepatic oxalate production causing end-stage renal
disease. A single systemic administration of an AAV8-CRISPR/Cas9 vector targeting gly-
colate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity
in Agxt1−/−mice. Our results reveal that CRISPR/Cas9-mediated SRT represents a promising
therapeutic option for PH1 that can be potentially applied to other metabolic diseases caused
by the accumulation of toxic metabolites.
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Primary hyperoxalurias (PH) are a group of autosomalrecessive metabolic disorders characterized by defects inenzymes involved in glyoxylate metabolism. The disease is
caused by oxalate overproduction, an end-product of glyoxylate
metabolism with no biological role in mammals that is produced
in the liver and excreted by the kidney1,2. Under normal cir-
cumstances oxalate is produced at low levels and continuously
removed by the kidneys from blood and excreted in urine.
However, in PH patients renal accumulation of oxalate results in
urolithiasis, nephrocalcinosis and progression to end-stage renal
disease (ESRD)1,2. There are three PH forms (PH1, 2, and 3),
with PH1 being the most common (around 70–80% of all PH
patients)3,4 and severe subtype. PH1 is a life-threatening disease
caused by mutations in the AGXT gene leading to impaired
activity of the hepatic enzyme alanine-glyoxylate aminotransfer-
ase (AGT)5, which catalyzes glyoxylate conversion to glycine
(Fig. 1a). AGT malfunction results in progressive decrease of
glomerular ﬁltration rate (GFR), and ultimately leads to ESRD
and, if untreated, death in most patients6.
Early diagnosis and initiation of conservative therapy are cri-
tical in preserving adequate renal function for as long as possible7.
Existing treatments aim to ameliorate disease manifestations, but
once the renal function is compromised, combined kidney and
liver transplantation, with a better survival rate than isolated
kidney transplant8,9, is the preferred option10,11. Thus, new
therapeutic options are urgently needed. Novel molecular
approaches are currently under investigation, including the use of
oxalate degrading enzymes, correction of AGT mistargeting
(applicable only to a speciﬁc population of patients), as well as
gene and cell therapies12–17. An attractive therapeutic strategy for
diseases associated with the accumulation of toxic metabolic
products, like PH1, is based on a substrate reduction therapy
(SRT)18–20. In the context of PH1, inhibition of glycolate oxidase
(GO), the enzyme involved in the production of glyoxylate from
glycolate, has been postulated as a promising strategy21–24
(Fig. 1a). In fact, GO deﬁciency is a very rare disorder, with only
two published cases25,26, showing asymptomatic glycolic aciduria
as the only consequence of lack of GO activity. Moreover, in mice,
GO deﬁciency (Hao1−/−) results in an increased production of
glycolate, which is a highly soluble molecule that can be elimi-
nated in urine without inducing kidney damage or other related
toxicity21. Furthermore, with respect to the hyperoxaluric
Agxt1−/−mice, mice genetically deﬁcient in both Agxt1 and Hao1
genes (Agxt1−/−/Hao1−/−) have normal levels of oxalate excre-
tion in the absence of pathological ﬁndings21. In addition,
pharmacological GO inhibition using small molecules, or GO
silencing by small-interfering RNAs (siRNA), can also achieve a
signiﬁcant reduction in oxalate excretion in Agxt1−/− mice22–24.
The safety and efﬁcacy of GO silencing in PH1 patients is cur-
rently being investigated in ongoing clinical trials (Alnylam
Pharmaceuticals 2016, NCT02706886). However, although the
use of small molecules or siRNAs can be effective to block
disease-related pathways, they have limitations such as the
requirement of multiple administrations for long-term effect24,
incomplete inhibition of the target enzyme, compliance and
potential interactions of the small molecules with other drugs/
treatments27.
The latest advances in genome editing using sequence-speciﬁc
nucleases, particularly the bacterial type II clustered regularly
interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) sys-
tems28–30, provide essential tools that enable substantial progress
in the development of new therapies31–34. The CRISPR/
Cas9 system consists of a programmable single-guide RNA
(sgRNA), which directs Cas9 endonuclease to the desired geno-
mic locus followed by a consensus sequence (protospacer adjacent
motif, or PAM) to induce double-strand breaks (DSBs) into the
DNA. DSBs can be repaired by homologous recombination
(HDR) during the S/G2 phase of the cell cycle or by the error-
prone non-homologous end joining (NHEJ) machinery, which
can be exploited to induce insertions or deletions (indels) for gene
inactivation. Indeed, therapeutic approaches based on in vivo
CRISPR/Cas9 genome editing using both HDR and NHEJ have
been recently developed for different diseases, such are hemo-
philia35, Duchenne muscular dystrophy36–38, retinitis pigmen-
tosa39 or congenital metabolic diseases like hereditary
tyrosinemia type I40,41, urea cycle disorders42 or
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Fig. 1 Efﬁcient GO inhibition using CRISPR/Cas9 in PH1 animals. a Schematic representation of the CRISPR/Cas9-mediated SRT strategy targeting the Hao1
locus. b Editing efﬁciency measured by TIDE in 12–14-week-old PH1 animals 4 weeks after treatment with saline (n= 5), Cas9 (n= 5), Hao1-g1 (n= 5) and
Hao1-g2 (n= 5). c Quantiﬁcation of Hao1 mRNA expression levels by RT-qPCR in animals treated as in (b). Data are presented as mean ± SEM and
Kruskal–Wallis statistical test was used to evaluate differences between groups. dWestern blot analysis of GO protein levels in representative PH1 animals
treated with saline, Cas9, Hao1-g1, and Hao1-g2. GAPDH was used as loading control. e Representative IHC images of liver sections stained for GO, from
PH1 animals treated with saline, Cas9, Hao1-g1, and Hao1-g2. Scale bar: 100 μm. *p < 0.05
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hypercholesterolemia43. Although correcting the disease-causing
mutations by HDR represents the ideal approach for the treat-
ment of inherited liver metabolic diseases like PH1, this strategy
is still very inefﬁcient, due to the low mitotic index of hepatocytes
and the bias for the NHEJ pathway to repair DSBs. Furthermore,
since in PH1 the hepatocytes remain healthy and there is no liver
damage, the corrected hepatocytes have no advantage and will not
be selected to repopulate the liver as has been demonstrated for
other diseases like tyrosinemia40. We postulate that in vivo
CRISPR/Cas9-mediated SRT to genetically inactivate non-
essential enzymes of the glyoxylate pathway, such as GO, could
be an efﬁcient therapeutic approach for treating PH1 (Fig. 1a).
In this work, we established an AAV-based CRISPR/
Cas9 system for targeted gene disruption of murine Hao1 that
was evaluated in a preclinical mouse model of PH116. Our studies
showed that a single-dose administration of the therapeutic vec-
tor resulted in long-term inhibition of hepatic GO, which lead to
the reduction of urine oxalate excretion to normal levels and
prevented nephrocalcinosis formation with an absence of toxic
effects.
Results
Efﬁcient in vivo GO inhibition using CRISPR/Cas9. To develop
a CRISPR/Cas9-mediated in vivo GO inhibition strategy as
potential SRT for PH1, two single guide RNAs (sgRNA) targeting
exonic regions of the murine Hao1 gene were designed and
selected based on location and predicted high on-target and low
off-target efﬁciency (Supplementary Table 1). A single AAV8
vector, was used to deliver Staphylococcus aureus Cas9 (SaCas9)
and the Hao1 speciﬁc sgRNA to the liver of Agxt1−/− mice. To
restrict genome editing to hepatocytes, the expression of SaCas9
was controlled by the liver-speciﬁc thyroxine-binding globulin
(TBG) promoter44,45 (Supplementary Fig. 1a). Gene editing efﬁ-
ciency of the AAV8-SaCas9-Hao1-sgRNA system was evaluated
in 12–14-week-old PH1 male mice, which were treated intrave-
nously with AAV8-SaCas9-Hao1-sgRNA1 (Hao1-g1), AAV8-
Cas9-Hao1-sgRNA2 (Hao1-g2) or AAV8-SaCas9 without sgRNA
(Cas9), at a dose of 5 × 1012 vg/kg. A group of animals that
received saline were used as controls. Mice were sacriﬁced
4 weeks after treatment and vector genome copies and SaCas9
expression levels were evaluated, with no differences among the
groups that received the vectors (Supplementary Fig. 1b and 1c).
Cleavage efﬁcacy was analyzed by SURVEYOR assay and indel
frequencies were measured by TIDE46 (Fig. 1b and Supplemen-
tary Fig. 1d). An average of 42.14 ± 7.81% and 56.32 ± 12.33% of
indels were detected in the livers of the animals having received
Hao1-g1 and Hao1-g2, respectively. Moreover, Hao1 transcrip-
tion levels were reduced in the animals receiving the therapeutic
vectors (Fig. 1c). In accordance, Western blot analysis showed a
dramatic reduction of GO protein expression (Fig. 1d). Further-
more, immunohistochemical analysis revealed small numbers of
isolated GO-positive cells in AAV8-SaCas9-Hao1-sgRNA-treated
animals, while control animals had a homogenous staining of the
hepatocytes (Fig. 1e).
Characterization of CRISPR/Cas9-mediated genome editing.
In order to better characterize genome editing efﬁciency and
variant distribution in the liver of animals treated with the
therapeutic vectors, the Hao1 targeted locus was ampliﬁed by
PCR to generate barcoded libraries that were analyzed by next-
generation sequencing (NGS). Deep sequencing of animals hav-
ing received Hao1-g1 or Hao1-g2 vectors (n= 5 per sgRNA)
conﬁrmed previous results with an indel average of 48.46 ± 3.41%
for Hao1-g1 and 52.81 ± 3.85% for Hao1-g2 (Fig. 2a and Table 1).
Interestingly, cleavage efﬁciency increased signiﬁcantly when
analyzed in puriﬁed hepatocytes, as expected due to the hepato-
speciﬁc expression of SaCas9 (Supplementary Fig. 1e). The most
common mutations for both sgRNAs were small indels under 10
bp (average of 80.66% for Hao1-g1 and 85.03% for Hao1-g2),
occurring around positions −3 to +3 relative to the cleavage site
(Fig. 2b and Supplementary Fig. 2). Interestingly, indel distribu-
tion was different between sgRNAs, with Hao1-g1 being prone to
introduce insertions of 1 bp, while Hao1-g2 more frequently
induced 2 bp deletions (Fig. 2b, c). Moreover, although insertions
were predominantly introduced at position +1 for both sgRNAs,
deletions were more widely distributed (Supplementary Fig. 2).
These differences in indel distribution might be due to the dif-
ferent target sites selected for each sgRNA, since Hao1-g1 targets
the 5’-end of the Hao1 exon 2 and Hao1-g2 is directed to the
middle of the same exon. More importantly, despite the differ-
ences in indel distribution, both sgRNAs introduced frameshift
mutations (88.45% and 80.42%, respectively), which explained the
reduction in protein levels (Fig. 2b).
Therapeutic efﬁcacy of CRISPR/Cas9-mediated SRT. We fur-
ther evaluated the efﬁcacy of CRISPR/Cas9-mediated GO inhi-
bition as a therapeutic treatment for PH1, aiming to reduce urine
oxalate levels and to prevent kidney damage (Fig. 3a). Thus, PH1
male mice were treated as described above with therapeutic and
control vectors. Since Agxt1−/− mice become hyperoxaluric with
respect to control WT littermates from 3 months of age
onwards16, we analyzed oxaluria levels in 24 h urine samples
collected 4 months after AAV administration (6–7 month-old
animals). Mice treated with Hao1-g1 and Hao1-g2 vectors pre-
sented with signiﬁcantly lower levels of urine oxalate than PH1
control groups (Cas9 and saline) and levels similar to those of
WT animals. This indicated that CRISPR/Cas9-mediated GO
inhibition reduced oxalate accumulation (Fig. 3b). As expected,
urine glycolate levels were increased as a result of GO reduction
(Fig. 3b). Since oxaluria is greatly increased after overload of the
glyoxylate pathway, therapeutic efﬁcacy was also analyzed in PH1
animals challenged during 7 consecutive days with ethylene glycol
(EG), a precursor of glyoxylate that increases oxalate
production17,22. Urine oxalate levels, measured on days 3 and 7 of
EG challenge, were signiﬁcantly lower in the animals that received
Hao1-g1 and Hao1-g2 than the PH1 control groups (Cas9 and
Saline), and more importantly, similar to levels observed in WT
animals (Fig. 3c). Again, as expected, signiﬁcantly higher urine
glycolate levels were observed in treated animals (Fig. 3d). No
difference in water intake was observed between the groups,
indicating a homogenous EG challenge (Supplementary Fig. 3a).
Previous studies have shown that EG challenge in WT mice,
which are capable of eliminating high concentrations of oxalate in
the urine, is well tolerated without any apparent toxic effect and
weight loss16. Interestingly, in contrast to Cas9 and saline con-
trols, no body-weight loss was observed during the challenge in
animals treated with the therapeutic vectors, indicating the efﬁ-
ciency of the CRISPR/Cas9-mediated SRT treatment (Fig. 3e).
CRISPR/Cas9-mediated SRT prevented nephrocalcinosis. Since
Agxt1−/− mice develop varying degrees of kidney calcium oxalate
deposits when challenged with EG16, the capacity of the treatment
to prevent nephrocalcinosis was also analyzed. Thus, PH1 ani-
mals were treated with the therapeutic vectors as described above,
and two groups of control animals (saline and Cas9) were
included. To induce nephrocalcinosis animals were challenged
with EG for a longer period of time (10 days), and kidney his-
tology was analyzed. While control animals showed varying
degrees of calcium oxalate (CaOx) deposits in their kidneys,
with 3 out of 8 animals developing severe or moderate
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nephrocalcinosis (3.2–6.2% of kidney area presenting CaOx
crystals, Fig. 3f and Supplementary Fig. 3b), only 1 out of 10
animals treated with the therapeutic vectors displayed mild CaOx
deposition (0.7% of kidney area presenting CaOx crystals, Fig. 3f
and Supplementary Fig. 3b). These results indicate that our
CRISPR/Cas9-mediated SRT strategy was able not only to reduce
the urine oxalate levels, but also to protect against kidney stone
formation caused by prolonged hyperoxaluria in a PH1 mouse
model.
Safety of CRISPR/Cas9-mediated SRT therapy. One of the main
concerns regarding therapies involving CRISPR/Cas9 is the
potential genotoxic effect due to non-speciﬁc cleavage and off-
target indel generation. To address this question, we performed
targeted deep sequencing at the on-target site as well as the
predicted off-target regions (top 7 score, Benchling) for each
sgRNA in the livers of treated animals 6 months after AAV
administration (Supplementary Table 2). In comparison to the
data obtained 4 weeks after vector injection, we observed slightly
Table 1 Average percentage of variants in on-target and off-target sites
Target Site Time after treatment Group ONT OFT1 OFT2 OFT3 OFT4 OFT5 OFT6 OFT7
Hao1-g1 4 weeks Saline (n= 1) 0.14 0.12 0.1 0.03 0.08 0.01 0.26 0.11
Cas9 (n= 3) 0.18 0.17 0.09 0.06 0.08 0.04 0.3 0.08
Hao1-g1 (n= 5) 48.46 0.18 0.08 0.05 0.08 0.04 0.29 0.08
6 months Saline (n= 1) 0.14 0.12 0.1 0.03 0.08 0.01 0.26 0.11
Cas9 (n= 3) 0.24 0.18 0.07 0.06 0.07 0.04 0.28 0.07
Hao1-g1 (n= 5) 60.57 0.19 0.08 0.05 0.07 0.03 0.32 0.1
Hao1-g2 4 weeks Saline (n= 1) 0.14 0.12 0.1 0.03 0.08 0.01 0.26 0.11
Cas9 (n= 3) 0.08 0.07 0.09 0.09 0.06 0.07 0.1 0.11
Hao1-g2 (n= 5) 52.81 0.08 0.09 0.08 0.06 0.06 0.13 0.11
6 months Saline (n= 1) 0.14 0.12 0.1 0.03 0.08 0.01 0.26 0.11
Cas9 (n= 3) 0.08 0.07 0.09 0.1 0.08 0.06 0.11 0.12
Hao1-g2 (n= 5) 60.13 0.07 0.08 0.08 0.07 0.07 0.1 0.12
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Fig. 2 Characterization of CRISPR/Cas9-mediated Hao1 gene editing. Deep sequencing was performed 1 month after treatment on the DNA from livers of
12–14-week-old PH1 animals treated with Hao1-g1 (n= 5) and Hao1-g2 (n= 5), as well as Cas9 (n= 3) and saline (n= 1). a Frequency of CRISPR/Cas9
introduced variants in the Hao1 gene of individual animals. b Characterization of the variants according to their type, size, and frameshift potential of each
animal treated with Hao1-g1 and Hao1-g2. a, b Each bar represents an individual mouse. c Frequency distribution of indel size in base pairs (bp) for each
animal treated with Hao1-g1 (green lines) and Hao1-g2 (orange lines). Each line represents an individual mouse
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increased indel frequencies at the Hao1 locus for both sgRNAs
(60.57 ± 1.80% and 60.13 ± 5.90%, respectively) (Table 1 and
Supplementary Fig. 4). These differences are probably due to
variability between experiments. Again, the variants introduced
were similar to previous observations, with the most common
mutations being small indels (<10 bp) triggering a frameshift and
with a different indel distribution for each sgRNA (Supplemen-
tary Fig. 4). However, none of the frequencies observed at the off-
target regions (OFT1 to OFT7) were substantially higher than the
background indel rate observed in control animals (usually <0.1%
due to sequencing errors) (Table 1). We also analyzed the on-
target sites in different tissues, to corroborate the hepato-
speciﬁcity of our therapeutic vectors. Again, none of the fre-
quencies observed were substantially higher than the control mice
(Supplementary Table 3). These results indicate that our ther-
apeutic approach is tissue-speciﬁc and there is no in vivo off-
target effect in the predicted higher scoring regions for both Hao1
sgRNAs.
Furthermore, we also analyzed the potential hepatotoxicity of
the treatment by studying the histopathology and measuring
serum transaminase and bilirubin levels. As shown in Fig. 4a, the
livers of treated animals showed normal histology, and
CD45 staining of leukocytes revealed no inﬂammatory inﬁltrate
(quantiﬁed in Fig. 4b). The levels of both serum biochemical
parameters remained normal in animals receiving the therapeutic
vectors (Fig. 4c, d). Moreover, the weight of the animals was
monitored weekly during the experiments and normal weight-
gain was observed in all the groups before the EG challenge
(Supplementary Fig. 5). Although safety in patients cannot be
fully predicted, all together, these data suggest that the CRISPR/
Cas9-mediated GO inhibition approach to treat PH1 is safe.
Discussion
The latest advances in CRISPR/Cas9 technology31,34 have cata-
lyzed the rapid development of new therapies not only for con-
genital metabolic disease but also for many other inherited
disorders, which have shown promising outcomes in animal
models35–43. In addition to genetic diseases, CRISPR/Cas9 gene
editing has also been applied to cancer immunotherapy by
engineering autologous T-cells to express chimeric antigen
receptors, and to infectious diseases, where genome editing can
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modify receptors that are essential for the pathogenesis of viral
infections47.
In this study, we have developed an SRT for primary hyper-
oxaluria type I (PH1) based on CRISPR/Cas9-mediated gene
editing. We have demonstrated that a sustained and highly sig-
niﬁcant reduction of GO protein expression can be achieved after
a single delivery of an AAV vector carrying both Staphylococcus
aureus Cas9 and GO-speciﬁc sgRNAs to the livers of mice with
PH1. The high editing efﬁciency of the system is translated into
an outstanding therapeutic effect. Our results clearly demonstrate
that renal oxalate accumulation is prevented in treated mice and
that they were fully protected against metabolic challenge with an
oxalate precursor (EG), showing reduced oxalate excretion in
urine and reduced oxalate crystal formation in the kidneys. The
detection of indels in treated animals by 3 different methods
(Surveyor, TIDE, and NGS) revealed an average of 50–60% of
indels, while the GO protein remained undetectable. The reason
for the apparent discrepancy between indel frequency and GO
disappearance is due to the fact that we performed indel analysis
using whole liver samples, which include hepatocytes as well as
nonparenchymal cells. Since SaCas9 nuclease expression is
restricted to the hepatocytes44,45, the Hao1 gene remains intact in
the rest of the liver cells. Accordingly, the cleavage efﬁciency
increased when measured in puriﬁed hepatocytes, explaining the
signiﬁcant effect observed at protein levels. Similar discrepancies
were previously observed when targeting other liver enzymes
using CRISPR/Cas943,44.
The therapeutic approach developed in this work was safe
during the period of the treatment. The only side effect detected
when editing Hao1 was a signiﬁcant increase of glycolate levels in
urine, which is considered non-pathological. Similar results were
previously reported in mice deﬁcient in both Agxt and Hao121,
and mice treated with Hao1 siRNA22,23. Furthermore, normal
liver histology with no elevation of liver transaminase or bilirubin
was observed, indicating that vector administration caused no
liver damage. As mentioned, the off-target effect of CRISPR/
Cas9 systems is probably the most concerning issue for in vivo
therapeutic applications. An important consideration is that a
Cas9 nuclease delivered by AAV will be expressed during the
whole life of the mice, increasing the probability of non-speciﬁc
genome modiﬁcation in the long-term. However, several pub-
lished studies have showed that undesired mutations attributable
to Cas9 are rare48–50. Nevertheless, the fact that those studies
were performed using zygotes and that the presence of mutations
was analyzed in the offspring, make it difﬁcult to compare with a
treatment applied to adult mice in a fully mature organ with low
cell turnover. In our study, the therapeutic vectors induced liver-
speciﬁc on-target cleavage, and more interestingly, no off-target
effect was observed by NGS at the potential off-target sites in
animals treated for at least six months; results that are in
accordance with previous studies using similar systems not only
in the liver40–42 but also in other tissues like muscle36–38. How-
ever, while more experiments are required for an unbiased ana-
lysis of non-speciﬁc SaCas9 cleavage, there are different
alternatives to decrease the probability of off-target modiﬁcations,
such as the use of the most up-to-date sgRNA design algorithms
and selection of guides with low predicted off-target potential51,
or the use of new delivery methods to express or deliver the
CRISPR/Cas9 system transiently, which should be sufﬁcient to
modify the two Hao1 alleles. Other alternatives to increase spe-
ciﬁcity and to eliminate potential off-target effects would be the
use of a mutated nickase Cas9 version52, which only introduces
single-strand breaks and requires the use of two sgRNAs, or high-
ﬁdelity or self-inactivating Cas9 variants53,54.
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Fig. 4 Safety of the expression of CRISPR/Cas9 system. a Representative hematoxylin-eosin staining and CD45+ IHC of liver sections from 8–10-week-old
PH1 animals sacriﬁced 4 months after treatment with saline (n= 7), Cas9 (n= 6), Hao1-g1 (n= 6) and Hao1-g2 (n= 5). Scale bar: 200 μm. b Quantiﬁcation
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treatment. Mean ± SEM of data are presented. Kruskal–Wallis test revealed no signiﬁcant differences between groups. Dotted lines represent the range of
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An additional safety concern of the CRISPR/Cas9 system is the
immunogenicity of Cas9. Recent ﬁndings indicate that cellular
and humoral responses against this protein are developed
in humans infected with S. pyogenes or S. aureus55. Moreover,
AAV-mediated expression of SpCas9 in the muscle of mice also
triggered immune responses56. However, in our study immunity-
related events were not observed in PH1 mice treated with the
AAVs expressing SaCas9, since Cas9 expression was not lost and
the quantiﬁcation of the hepatic immune inﬁltrate did not reveal
differences between treated and control groups. Nevertheless,
additional analysis should be performed in order to clarify this
point and further develop these CRIPSR/Cas9-mediated SRTs as
a therapeutic option for metabolic life-threatening diseases that
are due to the accumulation of toxic metabolites.
In summary, we have demonstrated that a single administration
of an AAV-CRISPR/Cas9 editing vector, targeting one of the
enzymes of the glyoxylate metabolic pathway, results in an extra-
ordinary therapeutic effect in PH1 mice in the absence of selective
advantage. Our results corroborate the high efﬁciency of the
CRISPR/Cas9 system to knock out the expression of a liver-speciﬁc
protein in vivo using AAV vectors. Our CRISPR/Cas9-based SRT
for PH1 would help to overcome limitations associated with siRNA-
mediated approaches that are currently being investigated, avoiding
the requirement of multiple administrations for long-term effect24,
which would clearly beneﬁt the quality of life of patients and
families. The treatment has been demonstrated to be safe in a PH1
mouse model but more studies in other models need to be per-
formed in order to predict better possible adverse events in patients.
Overall, our data provide support to the use of CRIPSR/Cas9-
mediated GO depletion as an effective and alternative promising
therapeutic strategy for PH1 patients. Furthermore, CRISPR/Cas9-
based SRTs could be applied to PH2 and PH3 by targeting other
enzymes involved in glyoxylate metabolism, such as lactate dehy-
drogenase (LDH) or hydroxyproline dehydrogenase (HYPDH or
PRODH2). In particular, liver-speciﬁc suppression of Ldha mRNA
expression by siRNA efﬁciently reduces urinary oxalate levels in all
tested hyperoxaluria animal models57. Moreover, CRISPR/Cas9-
based SRTs could also be applied to other inherited metabolic
diseases, such as lysosomal storage disorders (LSD) in particular.
For example, inhibition of Gly1 has been proposed as a therapeutic
approach for Pompe disease58, while Ext1 and Ext2 inhibition
reduces disease-speciﬁc biomarkers and the effects caused by
heparan sulfate accumulation in Mucopolysaccharidoses type III59.
Thus, CRISPR/Cas9-mediated inhibition of these genes could offer
a potential therapeutic approach for these devastating diseases.
Methods
CRISPR/Cas9 vectors and gRNA design. The pX602-AAV-TBG::NLS-SaCas9-
NLS-HA-OLLAS-bGHpA;U6::BsaI-sgRNA plasmid that contains the Staphylo-
coccus aureus Cas9 (SaCas9) expressed under the tTBG promoter, the sgRNA
under U6 promoter and ITR sequences for AAV vector production was a gift from
Feng Zhang (Addgene plasmid # 61593)44. sgRNAs targeting exonic regions of the
Hao1 gene were designed and selected using Benchling software (www.benchling.
com). The selected 21-nt sequences upstream of the 5’-NNGRRT-3’ PAM sequence
of SaCas9 are shown in Supplementary Table 1. Annealed oligonucleotides (Sigma)
were cloned into BsaI site of pX602 vector using standard molecular cloning
techniques.
AAV8 vector production. Serotype 8 AAV vectors containing each Hao1 sgRNA
were produced in HEK293T (ATCC CRL-3216) packaging cells as described60.
Brieﬂy, for each production, the shuttle vector for AAV and the packaging plasmid
pDP8.ape (Plasmid factory) were co-transfected into HEK293T cells. The cells and
supernatants were harvested 72 h upon transfection and virus was released from
the cells by three rounds of freeze–thawing. Crude lysate from all batches was then
treated with DNAse and RNAse (0.1 mg per p150 culture dish) for 1 h at 37 °C and
then kept at −80 °C until puriﬁcation. Puriﬁcation of crude lysate was performed
by ultracentrifugation in Optiprep Density Gradient Medium-Iodixanol (Sigma-
Aldrich). Thereafter, iodioxanol was removed and the batches concentrated by
passage through Amicon Ultra-15 tubes (Ultracel-100K; Merck Millipore). AAV8
vector without sgRNA (Cas9) was produced as control. For virus titration, viral
DNA was isolated using the High Pure Viral Nucleic Acid kit (Roche Applied
Science). Viral titers in terms of viral genome per milliliter (vg/mL) were deter-
mined by qPCR (Applied Biosystems) using SaCas9 speciﬁc primers (Supple-
mentary Table 4).
Animal procedures. All experimental procedures were approved by the Ethics
Committee of the University of Navarra and the Institute of Public Health of
Navarra according to European Council Guidelines. All the experiments using
animal models complied with all relevant ethical regulations. Agxt1−/− mice
(B6.129SvAgxttm1Ull) mice were bred and maintained in a pathogen-free facility
with free access to standard chow and water. Agxt1−/− mice were genotyped as
described16, by using KAPA HotStart Mouse Genotyping Kit (Kapa Biosystems)
with wild-type and mutant-speciﬁc primers together with a common forward pri-
mer (Supplementary Table 4). Age-matched C57BL/6J mice (Harlan laboratories)
were used as control animals. 5 × 1012 vg/kg were administered to 12–14-week-old
Agxt1−/− male animals (in short-term studies) or 8–10-week-old Agxt1−/− animals
(long-term studies) by intravenous injection. Animals were continuously challenged
with 0.5% (v/v) EG in drinking water for 7–10 days. During the challenge, mice
were individualized in metabolic cages for the collection of 24 h urine and mon-
itoring of water intake. Urine samples were obtained before, and on days 3 and 7
during the challenge. Serum samples were obtained before the euthanasia and liver
and kidney samples during the necropsy.
Genomic DNA extraction and indel quantiﬁcation. Genomic DNA was extracted
from tissue sections using NucleoSpin Tissue DNA extraction kit (Macherey-
Nagel) according to the manufacturer’s instructions. The efﬁciency of each indi-
vidual sgRNA was tested by surveyor using the Surveyor® Mutation Detection Kit
(IDT) following the manufacturer’s instructions. Uncropped electrophoresis gels
are available as Supplementary Information (Supplementary Fig. 6). Indel per-
centage was calculated by sequencing the ampliﬁcation products of Hao1 gene exon
2 and comparing the chromatograms with control samples using TIDE webtool
(https://tide.nki.nl)46.
On-target and off-target mutagenesis analyses. To further analyze off-target
sites, the most likely off-target sites for each selected sgRNA were determined using
Benchling software (www.benchling.com) (Supplementary Table 2). A total of 7
off-target candidates were selected for each sgRNA. Primers spanning on-target
and off-target sites for each sgRNA (Supplementary Table 4) were used to amplify
relevant sequences by nested PCR. Brieﬂy, 50 ng of genomic DNA was ﬁrst
ampliﬁed using speciﬁc primers using KAPA HiFi HotStart ReadyMix PCR Kit
(Kapa Biosystems) and puriﬁed using Agencourt AMPure XP system (Beckman
Coulter). Then, for each sgRNA, equal amounts of puriﬁed amplicons from the
same sample were mixed. Nested PCR was performed using 10 ng of PCR mix and
universal primers with speciﬁc barcodes for each sample were used to generate
Illumina amplicons. PCR products were puriﬁed as described above. Final library
was made mixing equal amounts of the second PCR products and sequenced on
Illumina MiSeq (2 × 250 bp paired-end) at >25,000 × coverage at ampliﬁed regions.
Data were processed according to standard Illumina sequencing analysis proce-
dures. Processed reads were aligned to the reference (GRCm38/mm10) using
Burrows-Wheeler Aligner (BWA). Reads that did not map to the reference were
discarded. Insertions and/or deletions were determined by comparison of reads
against reference using CrispRVariants R-based toolkit61.
Liver transduction and gene expression by RT-qPCR. Genomic DNA was
extracted as explained above and qPCR was employed to quantify viral genome
copies in the liver using SaCas9 speciﬁc primers (Supplementary Table 4). RNA
was isolated using Trizol (Life Technology) and reverse-transcribed using Prime-
ScriptTM RT reagent Kit (Takara). qPCR to quantify Hao1, SaCas9 and β-actin
were performed in a QuantStudio™ 5 Real-Time PCR System (ThermoFisher Sci-
entiﬁc) or a CFX96™ Real-Time PCR Detection System (Bio-Rad) using gene-
speciﬁc primers (Supplementary Table 4). Data were normalized to β-actin levels.
GO detection by western blot and immunohistochemistry. For the detection of
GO by western blot, liver total proteins were extracted using RIPA Buffer and
quantiﬁed using BCA Protein Assay Kit (ThermoFisher Scientiﬁc). Proteins were
separated using a 15% acrylamide gel and blotted in a nitrocellulose membrane.
Membranes were blocked using SuperBlock™ (TBS) Blocking Buffer (ThermoFisher
Scientiﬁc) and incubated with anti-GO antibody (rabbit serum raised against
recombinant mouse GO protein) diluted 1:2500 overnight (o/n) at 4 °C in Blocking
Solution. The membranes were washed using TBS-0.05% Tween solution. Anti-
GAPDH antibody (#G8795, Sigma-Aldrich) was used at 1:5000 dilution during 2 h
at RT as internal reference. SuperSignal West Femto Maximum Sensitivity Sub-
strate (ThermoFisher Scientiﬁc) was used for the development of the signal after
incubation with the corresponding secondary antibody (HRP-conjugated anti-
rabbit IgG #NA934V from GE Healthcare at 1:2500 dilution or HRP-conjugated
anti-mouse IgG #NA931V from GE Healthcare at 1:5000 dilution) during 1 h at
RT. Odyssey Fc (LI-COR) imaging system was used for image generation.
Uncropped blots are available as Supplementary Information (Supplementary
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Fig. 7). Formalin-ﬁxed parafﬁn-embedded liver sections were used for immuno-
histochemical detection of GO using Benchmark Ultra equipment and reagents
(Ventana). Antigen retrieval was performed at 95 °C in high pH buffer (CC1,
Ventana) for 24 min, and followed by incubation with anti-GO rabbit serum
diluted 1:500 during 28 min at 37 °C. Next, polymeric HRP-conjugated anti-rabbit
IgG secondary antibody (#760-4311, Ventana Discovery Systems) at 1:1000 dilu-
tion was applied and a chromogenic signal was developed with DAB and copper
enhancement (Ventana).
Urine oxalate/glycolate measurement and serum biochemistry. Individual 24 h
urines were collected in 50 μl of 5 N HCl and their volume was measured. The
urines were treated with activated charcoal and urine oxalate levels were measured
using the Oxalate kit (Trinity Biotech) according to the manufacturer’s instruc-
tions. Oxalate quantiﬁcation (μmol/24 h) was calculated using the oxalate con-
centration and the urine volume. Glycolate concentration in charcoal-treated urine
samples was measured in a colorimetric assay using recombinant GO enzyme in
50 mM potassium phosphate buffer pH 7, coupled with HRP in the presence of
sulfonated-DCIP and 4-aminoantipyrine (Sigma Aldrich) as chromogens. The
absorbance was measured relative to a glycolate standard curve 515 nm62. Per-
ipheral blood samples were collected at the indicated time points, and the serum
was separated from whole blood after centrifugation at 845xg for 15 minutes.
Serum alanine aminotransaminase (ALT) and bilirubin levels were quantiﬁed using
a Cobas C111 analyzer (Roche).
Histological analysis of kidney. Tissues were ﬁxed in 4% buffered paraformalde-
hyde and either embedded in parafﬁn or cryoprotected in 20% sucrose and snap
frozen in liquid nitrogen. Routine hematoxylin-eosin stained sections were analyzed
under dark ﬁeld optics to count typical birefringent oxalate deposits. Three cortical
areas were photographed with a ×5 objective lens in a microscope (Leica DMLB)
ﬁtted with polarization ﬁlters to generate a dark ﬁeld in which calcium oxalate crystals
are seen as bright object. Digitized images were treated with ImageJ software to
calculate the percentage area above a threshold established with a normal kidney slide
photographed with the same settings. Four ranks of nephrocalcinosis were stablished
depending on crystal quantiﬁcation: negative (0%), mild (0–0.99%), moderate (1–5%),
and severe (>5% area occupied by calcium oxalate crystals).
Hematoxylin-eosin staining and CD45+ IHC in liver sections. Liver was har-
vested and ﬁxed in 4% formalin. Parafﬁn liver sections (3 µm thick) were cut,
dewaxed and hydrated. Hematoxylin-eosin staining was performed for structural
analysis. For IHC, antigen retrieval was applied: 2 µg/ml proteinase K (Sigma) for
30 min at 37 °C or heating for 30 min at 95 °C in 0.01 M Tris-1 mM EDTA pH 9
in a Pascal pressure chamber (Dako). Endogenous peroxidase was blocked with
3% H2O2 in deionized water for 10 min and sections were washed in TBS-0.05%
Tween 20. Incubation with rat anti-CD45 primary antibody (#103102, Biolegend)
at 1:2000 dilution was performed overnight at 4 °C. After rinsing in TBS-T, the
sections were incubated with the rabbit anti-rat IgG secondary antibody (#E0468,
Dako) for 30 min at RT followed by incubation with EnVision anti-rabbit
(#K401, Dako) for other 30 min at RT. Peroxidase activity was revealed using
DAB+ and sections were lightly counterstained with Harris hematoxylin. Finally,
slides were dehydrated in graded series of ethanol, cleared in xylene and mounted
with Eukitt (Labolan).
Statistics. All the results are presented as mean ± standard error of the mean
(SEM) of at least ﬁve mice per group at each time point to ensure reproducibility.
Sample sizes are noted in ﬁgure legends. Graphs and statistical analyses were
performed using GraphPad Prism 7.0d. Kruskal–Wallis test with Dunn’s post-test
was used to analyze differences between groups. Friedman test with Signs post-test
was used for comparison between different administration groups at different
times. Mann–Whitney test was used for individual comparisons. p-values < 0.05
were considered signiﬁcant.
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